Chemiluminescent Immunometric Assay
Assessment of prenatal risk for Down Syndrome (Trisomy 21), neural tube defects (NTD), and Edwards Syndrome (Trisomy 18).
Interpretive report provided.
Specimen must be from a patient with a maternal gestation of between 15 weeks 0 days and 22 weeks 6 days. Specimens with a maternal gestation after this time period will automatically be forwarded to Michigan State University for testing. MLabs recommends that specimens with a maternal gestation of less than 15 weeks be re-collected at a later time period.
2 - 3 days
- Quad Screen Maternal Serum
- AFP, Quad Test Profile
- Alpha Fetoprotein, Quad Test Profile
- Quadruple Test
- Triple Test Replacement Assay
- Edwards Syndrome (Trisomy 18) Risk
- Neural tube defects (NTD) Risk
- Prenatal risk for fetal congenital abnormalities
- Down Syndrome (Trisomy 21) Risk
Collect specimen in a red top tube from a patient with a maternal gestation of between 16 weeks 0 days and 22 weeks 6 days. Centrifuge, aliquot serum into a plastic vial within 2 hours of collection and refrigerate. (Frozen is also acceptable). Please provide a completed QUAD/AFP Requisition available online at http://mlabs.umich.edu/files/pdfs/REQ-QUAD_refr.pdf or the following information: gestational age (weeks and days on first ultrasound date >6 weeks 0 days; if ultrasound information is not available record first days of last menstrual period), maternal weight, maternal date of birth, insulin-dependent diabetes status prior to pregnancy, multiple gestation (single, twin, triplets), race, and previous history of Down syndrome or neural tube defect (NTD) pregnancy for the patient.
Test includes Alpha Fetoprotein (AFP), Beta Subunit of Human Chorionic Gonadotropin (hCG), Unconjugated Estriol (UE3), and Inhibin A. If there is a family history of neural tube defects, consultation with a genetic counselor to more accurately assess increased risk for neural tube defects is recommended. Test sent to Warde Medical Laboratory.